These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 33966812)

  • 1. Main barriers in the management of dyslipidaemias: Intolerants.
    Mostaza JM; Lahoz C
    Clin Investig Arterioscler; 2021 May; 33 Suppl 1():40-45. PubMed ID: 33966812
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Strategies to overcome statin intolerance.
    Agouridis AP; Nair DR; Mikhailidis DP
    Expert Opin Drug Metab Toxicol; 2015 Jun; 11(6):851-5. PubMed ID: 25786568
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systematic review: comparative effectiveness and harms of combination therapy and monotherapy for dyslipidemia.
    Sharma M; Ansari MT; Abou-Setta AM; Soares-Weiser K; Ooi TC; Sears M; Yazdi F; Tsertsvadze A; Moher D
    Ann Intern Med; 2009 Nov; 151(9):622-30. PubMed ID: 19884623
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bempedoic Acid: a cholesterol lowering agent with a novel mechanism of action.
    Nguyen H; Akamnonu I; Yang T
    Expert Rev Clin Pharmacol; 2021 May; 14(5):545-551. PubMed ID: 33691561
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical development of bempedoic acid: phase 2 and phase 3 clinical trials.
    Lekuona I; Pintó X
    Clin Investig Arterioscler; 2021 May; 33 Suppl 1():58-64. PubMed ID: 33966815
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Combined treatment: regimens, indications and safety profile].
    Muñiz Grijalvo O; Villar Ortiz J
    Clin Investig Arterioscler; 2013; 25(3):140-5. PubMed ID: 23880257
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Determinants of inertia with lipid-lowering treatment in patients with type 2 diabetes mellitus.
    García Díaz E; Ramírez Medina D; Morera Porras ÓM; Cabrera Mateos JL
    Endocrinol Diabetes Nutr (Engl Ed); 2019 Apr; 66(4):223-231. PubMed ID: 30541682
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dyslipidaemias and their treatment in high complexity centres in Colombia.
    Ruiz ÁJ; Vargas-Uricoechea H; Urina-Triana M; Román-González A; Isaza D; Etayo E; Quintero A; Molina DI; Toro JM; Parra G; Merchán A; Cadena A; Yupanqui Lozano H; Cárdenas JM; Quintero ÁM; Botero R; Jaramillo M; Arteaga JM; Vesga-Angarita B; Valenzuela-Plata E; Betancur-Valencia M
    Clin Investig Arterioscler; 2020; 32(3):101-110. PubMed ID: 32284160
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Second-line treatments for dyslipidemia in patients at risk of cardiovascular disease.
    Kondo Y; Hamai J; Nezu U; Shigematsu E; Kamiko K; Yamazaki S; Yoshii T; Takahashi M; Takano T; Kawasaki S; Yamada M; Yamakawa T; Terauchi Y
    Endocr J; 2014; 61(4):343-51. PubMed ID: 24452015
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Residual risk of cardiovascular complications and its reduction with a combination of lipid lowering agents].
    Soska V
    Vnitr Lek; 2011 Mar; 57(3):313-6. PubMed ID: 21495414
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bempedoic Acid in the Treatment of Patients with Dyslipidemias and Statin Intolerance.
    Susekov AV; Korol LA; Watts GF
    Cardiovasc Drugs Ther; 2021 Aug; 35(4):841-852. PubMed ID: 33502687
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic targets in the treatment of dyslipidaemias: From statins to PCSK9 inhibitors. Unmet needs.
    López-Miranda J; Pedro-Botet J
    Clin Investig Arterioscler; 2021 May; 33 Suppl 1():46-52. PubMed ID: 33966813
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [A new approach to the treatment of dyslipidemia].
    Kevelaitiene S; Slapikas R
    Medicina (Kaunas); 2008; 44(5):407-13. PubMed ID: 18541958
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changes in LDL-C levels and goal attainment associated with addition of ezetimibe to simvastatin, atorvastatin, or rosuvastatin compared with titrating statin monotherapy.
    Foody JM; Toth PP; Tomassini JE; Sajjan S; Ramey DR; Neff D; Tershakovec AM; Hu H; Tunceli K
    Vasc Health Risk Manag; 2013; 9():719-27. PubMed ID: 24265554
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Statins and PCSK9 inhibitors: A new lipid-lowering therapy.
    Gallego-Colon E; Daum A; Yosefy C
    Eur J Pharmacol; 2020 Jul; 878():173114. PubMed ID: 32302598
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An expert opinion paper on statin adherence and implementation of new lipid-lowering medications by the ESC Working Group on Cardiovascular Pharmacotherapy: Barriers to be overcome.
    Drexel H; Coats AJS; Spoletini I; Bilato C; Mollace V; Perrone Filardi P; Rosano GMC
    Eur Heart J Cardiovasc Pharmacother; 2020 Apr; 6(2):115-121. PubMed ID: 31873726
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Update of planning tables of cholesterol-lowering therapy orientated to achieve LDL therapeutic targets].
    Masana L; Plana N
    Clin Investig Arterioscler; 2015; 27(3):138-43. PubMed ID: 25865752
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Safety of Further Lowering of Low-Density Lipoprotein Cholesterol in Patients Starting With Very Low Levels: A Meta-analysis.
    Sabatine MS; Wiviott SD; Im K; Murphy SA; Giugliano RP
    JAMA Cardiol; 2018 Sep; 3(9):823-828. PubMed ID: 30073316
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [New indications and therapeutic objectives for dyslipidemia].
    Maiques Galán A
    Aten Primaria; 2006 Nov; 38(9):473-5. PubMed ID: 17194348
    [No Abstract]   [Full Text] [Related]  

  • 20. Role of Non-Statins, LDL-C Thresholds, and Special Population Considerations: A Look at the Updated 2016 ACC Consensus Committee Recommendations.
    Adhyaru BB; Jacobson TA
    Curr Atheroscler Rep; 2017 Jun; 19(6):29. PubMed ID: 28500517
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.